P1B budget for HIV treatment projected by 2022


    THE government’s budget for the treatment of Filipinos living with the human immunodeficiency virus (HIV) is projected to more than double when President Duterte’s term ends in 2022 as the number of patients continue to rise.

    Anakalusugan party-list Rep. Michael Defensor yesterday said the Department of Health (DOH) is already spending around P478 million annually for the 38,279 Filipinos living with HIV and actually undergoing antiretroviral therapy (ART).

    “The amount is likely to balloon to P1 billion annually by 2022, as more Filipinos living with HIV emerge and seek treatment,” Defensor said in a statement.

    The cost of a single course of treatment for one HIV patient in a year is between P12,500 to P15,000, according to the DOH.

    “We assume that some 10,000 new HIV cases will be discovered annually over the next three years, and that the DOH will succeed in getting 90 percent of them to undergo ART,” Defensor said.

    The administration lawmaker said the 10,000 patients is a fair estimate, considering that based on DOH data, an annual average of 10,588 new HIV cases were diagnosed countrywide between 2016 and 2018.

    From January to May this year, another 5,366 new HIV cases were recorded nationwide, according to the DOH’s National HIV and AIDS Registry.

    “Congress is absolutely committed to find ways to help the DOH achieve its 90-90-90 target in fighting HIV,” Defensor said.

    The DOH aims to diagnose 90 percent of all HIV cases in the country, treat 90 percent of those detected, and to suppress the virus in 90 percent of those receiving treatment.

    “We would also urge not just the DOH but also provincial, city and municipal health offices in regions with high HIV concentrations to invest more aggressively in preventive programs,” Defensor said.

    HIV causes AIDS, or the Acquired Immune Deficiency Syndrome, which destroys the human body’s natural ability to ward off all kinds of highly infectious diseases.

    Tuberculosis (TB) is one of the leading causes of death among people living with HIV in highly advanced stages, according to the World Health Organization (WHO).

    People living with HIV in the early stages can continue to live normally and be economically productive as long as their viral load is kept suppressed by ART, the WHO said.

    At present, the 38,279 Filipinos actually receiving ART represent only 57 percent of 67,395 cases listed in the National HIV and AIDS Registry as of May this year.